BioCentury
ARTICLE | Clinical News

Cytokinetics bags milestone as Amgen starts CVOT

December 2, 2016 12:32 AM UTC

Cytokinetics Inc. (NASDAQ:CYTK) said partner Amgen Inc. (NASDAQ:AMGN) started the Phase III GALACTIC-HF study of omecamtiv mecarbil (AMG 423) to treat chronic heart failure (CHF). The cardiovascular outcomes trial's launch triggers a $26.7 million milestone payment to Cytokinetics from Amgen (see BioCentury Extra, Sept. 1).

The trial will evaluate if the cardiac myosin activator is superior to placebo, if given with standard of care, in reducing the risk of cardiovascular death or heart failure events in high risk CHF patients with reduced ejection fraction...

BCIQ Company Profiles

Amgen Inc.

Cytokinetics Inc.

BCIQ Target Profiles

Cardiac myosin